Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Aptus Pharma IPO
Aptus Pharma Ltd
₹1,30,000 /2000 sharesMinimum Investment
Aptus Pharma IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 23 Sep ‘25 - 25 Sep ‘25 | ₹2,60,000 | 2,000 | ₹65 - ₹70 |
| Issue Size | IPO Doc |
|---|---|
| 13.02Cr | RHP PDF |
About Aptus Pharma
Founded in
2010
Managing director
Mr. Tejash Maheshchandra Hathi
Parent organisation
Aptus Pharma Ltd
Strengths & Financials of Aptus Pharma
Strengths
Risks
The company is ISO 9001:2015 certified for quality management systems, ISO 14001:2015 certified for environmental management systems, ISO 45001:2018 certified for occupational health and safety management, and GMP & GDP (good manufacturing practices and good distribution practices) certified.
As of FY25, the company claims to offer 194 pharmaceutical formulations across more than 11 therapeutic segments and has marketed over 75 brands.
The company states that its manufacturing partners are chosen through a strict evaluation of quality, compliance, and delivery standards. Each partner must hold WHO-GMP certification and undergo regular reviews and audits by the company’s quality assurance team. Before placing orders, the company further states that it verifies certifications, client base, production facilities, and delivery capacity, with documented agreements covering quality controls, packaging requirements, lead times, and logistics.
The company claims that its products have an established digital presence through distributors who list them on major online platforms such as 1MG and PharmEasy.
The company states that there is a comprehensive quality assurance system that ensures that every batch of pharmaceutical formulations undergoes real-time analytical testing during and after production. The company claims that these tests are performed in collaboration with certified, accredited laboratories to provide independent and reliable validation of product quality.
The company has witnessed a consistent increase in revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 13.90 crore in FY23 to Rs 17.86 crore in FY24 and Rs 24.56 crore in FY25. PAT increased from Rs 0.19 crore in FY23 to Rs 0.80 crore in FY24 and Rs 3.10 crore in FY25.
The company’s top 5 customers accounted for Rs 8.04 crore (32.74 percent) of the company’s total revenue in FY25, Rs 6.50 crore (36.39 percent) in FY24, and Rs 6.54 crore (47.09 percent) in FY23. Loss of any of these customers or a sudden decline in demand from them could adversely affect the company’s operations and finances.
The company reported negative cash flows from operating activities amounting to Rs 1.84 crore in FY25, Rs 2.17 crore in FY24, and Rs 0.18 crore in FY23. If cash outflows continue to exceed inflows, the company may face liquidity challenges in the future.
The company derives a significant portion of its revenue from Gujarat. The state accounted for Rs 24.36 crore (99.20 percent) of the company’s total revenue in FY25, Rs 17.86 crore (100 percent) in FY24, and Rs 13.90 crore (100 percent) in FY23. Any adverse political, social, or economic developments in these regions could adversely affect the company’s operations and financial performance.
The company markets and distributes pharmaceutical products but does not produce them itself. It relies on third-party manufacturers. So, issues like quality lapses, shipment delays, or preferential treatment of competitors could hit the company’s operations and profitability.
The company relies on external contract manufacturers for all its finished pharmaceutical formulations. While agreements are in place with these manufacturers, they do not include clear indemnity clauses for defective or substandard products. As a result, if patients, healthcare providers, or regulatory bodies such as the Central Drugs Standard Control Organisation (CDSCO) raise claims over product defects or adverse reactions, the company could face financial losses and legal actions.
The company’s business depends heavily on a large network of medical professionals, including general physicians, paediatricians, gynaecologists, cardiologists, endocrinologists, and neurologists, as well as chemists, pharmacies, and retail outlets. Any disruption in these relationships could negatively affect product distribution and overall operations.
The company and promoters are involved in certain ongoing litigation. Any adverse judgment in any of these cases could harm the company’s business prospects.
As of FY25, the company has a total indebtedness of Rs 10.36 crore. Any failure to service or repay these loans can harm the company’s operations and financial position.
Aptus Pharma Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Aptus Pharma IPO
| Apply as | Price band | Apply upto |
|---|---|---|
| Individual investor | ₹65 - 70 | ₹2 - 5 Lakh |
For Aptus Pharma IPO, eligible investors can apply as Individual investor.